Lasa Supergenerics Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 39 Cr | 20 Cr | 3 Cr |
| Operating expenses (approx.) | 57 Cr | 41 Cr | 7 Cr |
| EBITDA | -18 Cr | -21 Cr | -4 Cr |
| OPM % | -46.3% | -104.7% | -130.4% |
| Other income | 2 Cr | 0.13 Cr | 0.0070 Cr |
| Interest | 0.11 Cr | 0.03 Cr | 0.12 Cr |
| Depreciation | 4 Cr | 2 Cr | 2 Cr |
| Profit before tax | -22 Cr | -23 Cr | -6 Cr |
| Tax % | 35.4% | 6.3% | -10.1% |
| Net profit | -14 Cr | -21 Cr | -6 Cr |
| EPS (₹) | ₹-2.85 | ₹-4.22 | ₹-1.25 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 142 Cr | Sign in for TTM |
| Operating expenses (approx.) | 147 Cr | Sign in for TTM |
| EBITDA | -4 Cr | Sign in for TTM |
| OPM % | -3.1% | Sign in for TTM |
| Other income | 5 Cr | Sign in for TTM |
| Interest | 3 Cr | Sign in for TTM |
| Depreciation | 12 Cr | Sign in for TTM |
| Profit before tax | -19 Cr | Sign in for TTM |
| Tax % | 23.9% | Sign in for TTM |
| Net profit | -15 Cr | Sign in for TTM |
| EPS (₹) | ₹-2.95 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 50 Cr |
| Reserves | 34 Cr |
| Borrowings | 2 Cr |
| Other liabilities | 16 Cr |
| Total liabilities | 102 Cr |
| Fixed assets (net) | 48 Cr |
| CWIP | 0.25 Cr |
| Investments | 0.0000 Cr |
| Other assets | 33 Cr |
| Total assets | 102 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -3 Cr |
| Cash from investing | 8 Cr |
| Cash from financing | -6 Cr |
| Net cash flow | -0.33 Cr |
| Free cash flow (OCF − Capex) | -3 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -19.4% |
| ROE % | -17.6% |
| Debtor days | — |
| Inventory days | 82 |
| Days payable | — |
| Cash conversion cycle | 82 |
| Debt / equity | 0.03 |
| Current ratio | 1.90 |
| Net debt / EBITDA | — |
Compare with peers
Loading peers…